<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320966</url>
  </required_header>
  <id_info>
    <org_study_id>20-00037</org_study_id>
    <nct_id>NCT04320966</nct_id>
  </id_info>
  <brief_title>Neurovascular Complications and White Matter Damage in Acquired Anemias</brief_title>
  <official_title>Neurovascular Complications and White Matter Damage in Acquired Anemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational trial, in patients with moderate to severe anemia and control&#xD;
      subjects. The main purpose of this study is to understand whether normal brain blood flow,&#xD;
      oxygen extraction reserve, white matter volumes, and brain functional connectivity are&#xD;
      affected by acquired anemia. The investigators will perform baseline MRI monitoring for all&#xD;
      subjects. S All eligible subjects will be asked to provide informed consent before&#xD;
      participating in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational trial, in patients with moderate to severe anemia and control&#xD;
      subjects. The main purpose of this study is to understand whether normal brain blood flow,&#xD;
      oxygen extraction reserve, white matter volumes, and brain functional connectivity are&#xD;
      affected by acquired anemia. The investigators will perform baseline MRI monitoring for all&#xD;
      subjects. All eligible subjects will be asked to provide informed consent before&#xD;
      participating in the study. Comprehensive cerebrovascular MRI, baseline bloodwork, and&#xD;
      neurocognitive testing will be collected from all subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of acquired anemia on cerebrovascular oxygen delivery (ml O2/100g/min)</measure>
    <time_frame>Day 0</time_frame>
    <description>Impact of acquired anemia on cerebrovascular oxygen delivery will be assessed by measuring cerebral blood flow and oxygen content through MRI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of acquired anemia on cerebrovascular flow reactivity (%SI change/%ETCO2)</measure>
    <time_frame>Day 0</time_frame>
    <description>baseline MRI with blood oxygenation level dependent (BOLD) acquisition will be assessed in response to carbon dioxide exposure to determine whether acquired anemia affects cerebrovascular reserve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of acquired anemia on blood brain barrier permeability surface area product (ml H20/100g/min)</measure>
    <time_frame>Day 0</time_frame>
    <description>baseline PSA product using water-extraction-with-phase-contrast-arterial-spin-tagging (WEPCAST) MRI will be assessed to determine whether acquired anemia affects blood brain barrier permeability to water</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of acquired anemia on cerebral metabolic rate of oxygen (ml O2/100g/min)</measure>
    <time_frame>Day 0</time_frame>
    <description>T2 relaxation under spin tagging (TRUST) acquisition via MRI will be used to assess any impact of anemia on cerebral metabolic rate of oxygen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of acquired anemia on total brain blood flow (ml blood/100g/min)</measure>
    <time_frame>Day 0</time_frame>
    <description>Phase contrast MRI will be assessed to determine whether acquired anemia affects total brain blood flow</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Anemia</condition>
  <condition>Iron-deficiency Anemia</condition>
  <condition>Healthy Controls</condition>
  <arm_group>
    <arm_group_label>Acquired Anemia</arm_group_label>
    <description>Otherwise healthy individuals with hemoglobin below 10.5 g/dl or hematocrit below 32</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Age and sex matched individuals with hemoglobin in the upper quartile of normal</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        We will recruit anemic subjects from Blood Donor Centers across Los Angeles as well as the&#xD;
        abnormal Menstrual Bleeding Clinic at Children's hospital Los Angeles.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria (observational component):&#xD;
&#xD;
          1. Age between 16 and 60 years of age.&#xD;
&#xD;
          2. Any ethnicity.&#xD;
&#xD;
          3. Either sex.&#xD;
&#xD;
          4. Anemic group: hemoglobin less than 10.5 g/dl on screening hemoglobin.&#xD;
&#xD;
          5. Control group: hemoglobin &gt;13.2 g/dl for females, &gt;14.6 g/dl for males, comparable&#xD;
             age, sex and ethnicity to currently enrolled anemic subjects.&#xD;
&#xD;
        Exclusion criteria (observational component):&#xD;
&#xD;
          1. Diabetes requiring medication.&#xD;
&#xD;
          2. Hypertension requiring medication.&#xD;
&#xD;
          3. Sleep disordered breathing requiring intervention.&#xD;
&#xD;
          4. Body mass index &gt;35 (morbid obesity)&#xD;
&#xD;
          5. Contraindications to MRI, including pacemaker, severe claustrophobia, pregnancy.&#xD;
&#xD;
          6. Known systemic inflammatory disease such as inflammatory bowel disease, systemic lupus&#xD;
             erythematosus, or scleroderma.&#xD;
&#xD;
          7. Known HIV.&#xD;
&#xD;
        Inclusion criteria (interventional component):&#xD;
&#xD;
          1. Criteria for observational component, plus&#xD;
&#xD;
          2. Iron deficiency anemia based upon attending hematologist interpretation of transferrin&#xD;
             saturation, ferritin, and other ancillary labs including hs-CRP, MMA.&#xD;
&#xD;
        Exclusion criteria (interventional component):&#xD;
&#xD;
          1. Criteria for observational component, plus&#xD;
&#xD;
          2. Prior reaction to intravenous iron.&#xD;
&#xD;
          3. History of multiple drug allergies.&#xD;
&#xD;
          4. History of severe asthma, eczema, or atopy.&#xD;
&#xD;
          5. Systemic mastocytosis.&#xD;
&#xD;
          6. Severe respiratory or cardiac disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Wood, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silvie Suriany, MSc</last_name>
    <phone>(323) 361-4783</phone>
    <email>ssuriany@chla.usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Candice Mulder, MPh, CCRP</last_name>
    <phone>(323) 361-1646</phone>
    <email>cmulder@chla.usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope Blood Donor Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lefan Zhuang, MD</last_name>
      <email>lzhuang@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>Silvie Suriany, BS</last_name>
      <phone>626 373 7353</phone>
      <email>ssuriany@chla.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lefan Zhuang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedar Sinai Blood Bank</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-6062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ellen Klapper, MD</last_name>
      <email>Ellen.Klapper@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Silvie Suriany, BS</last_name>
      <phone>626 373 7353</phone>
      <email>ssuriany@chla.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ellen Klapper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvie Suriany, MSc</last_name>
      <phone>323-361-4783</phone>
      <email>ssuriany@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>John C Wood, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles Blood Donor Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dawn Ward, MD</last_name>
      <email>DWard@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Silvie Suriany, BS</last_name>
      <phone>626 373 7353</phone>
      <email>ssuriany@chla.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dawn Ward, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alyssa Ziman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Los Angeles</investigator_affiliation>
    <investigator_full_name>John C. Wood</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

